BlueCrest Capital Management’s Cytosorbents Corp CTSO Stock Holding History

BlueCrest Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-73,907	Closed	-$521K	–	1546
2018 Q1	$521K	Buy	73,907 +13,015	+21%	+$98.4K	0.02%	752
2017 Q4	$396K	Buy	+60,892	New	+$387K	0.01%	571
2015 Q2	–	Sell	-32,131	Closed	-$424K	–	811
2015 Q1	$424K	Buy	+32,131	New	+$331K	0.02%	483

Other funds holding CTSO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlueCrest Capital Management's CTSO Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Cytosorbents Corp (CTSO) in Q2 2018, closing a stake of 73,907 shares — an estimated $521K sold.

BlueCrest Capital Management first reported a position in CTSO in Q1 2015 and held it in 3 quarters. The position peaked at $521K in Q1 2018. 75 funds tracked by Wall St. Rank hold CTSO as of Q2 2018.

BlueCrest Capital Management reported no remaining Cytosorbents Corp position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 73,907 Cytosorbents Corp shares in Q2 2018, an estimated $521K.
BlueCrest Capital Management first reported a position in Cytosorbents Corp in Q1 2015 and held it in 3 quarters.
BlueCrest Capital Management's Cytosorbents Corp position peaked at $521K in Q1 2018.
75 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.